Objective
In developed countries, most HIV-infected patients are under highly active antiretroviral therapy (HAART). However, despite controlled viral replication, the immune reconstitution often remains incomplete, probably due to a poor reconstitution of thymic production. Apart its role in educating a diverse repertoire of conventional T-cells, the thymus also produces natural regulatory T-cells (nTreg), which contributes to the regulation of immune responses. Various cytokines are presently proposed as immunotherapy susceptible to help reconstituting circulating T-cell pool. Among these, Interleukin-7 is certainly the more promising as it directly affects thymic function, allowing T-cell neo-production and thus the enlargement of circulating T-cell repertoire diversity. The 3ITD project aims to a) analyze the physiology of nTreg production by the thymus; b) precisely evaluate the impact of acute SIV infection on nTreg production and identify the cytokines involved in early thymic defects; c) realize a pre-clinical study using recombinant IL-7 as a potential therapeutic to reconstitute nTreg subset in chronically HIV-infected patients and in HIV/HCV co-infected patients presenting with IFNα therapy-induced lymphopenia. The 3ITD project will be developed in 3 stages: a) definition of the phenotype of nTregs recently emigrated from the thymus; b) estimation of the impact of acute SIV infection and IFNα therapy; c) evaluation of the relevance of IL-7 treatment. The 3ITD project will provide a better understanding of the physiology of nTregs maturation by the thymus and of the modifications induced by HIV infection. Moreover, the 3ITD project will provide pre-clinical rationale for the use of IL-7 as a therapeutic compound in the treatment of virally- or pharmaceutically-induced nTreg deficiencies. It will impact the researcher’s growth and contribute to European excellence and knowledge transfer. Thus it is relevant to People specific, Capacity and Cooperation EC Program.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases RNA viruses hepatitis C
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine physiology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2009-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.